Bausch pays whopping $300M to settle Glumetza pay-for-delay lawsuit after 800% price hike
Bausch Health, which industry watchers may remember by its former name Valeant, has been riddled in controversy for years over its defense of diabetes med Glumetza. Now, the company will pay millions to put those charges to rest. Bausch has agreed to dish out $ 300 million to settle a 2019 lawsuit that claimed the Canadian drugmaker… Read More »